---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-008698"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-04-01T23:59:59+00:00"
generated_at: "2026-06-26T11:23:40.218736+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Oncotelic announces JV agreement signing, press release and 8-K forthcoming

## Summary
- Presented at MedInvest Pharmaceutical and Biotechnology Investor Conference on March 31, 2022.
- Company stated a joint venture agreement is being signed; further disclosure via press release and 8-K.
- No details on JV partner, terms, or timeline provided in the filing.
- Presentation and recording available on company website and YouTube channel.

## SEC filing metadata
- accession: 0001493152-22-008698
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222008698/0001493152-22-008698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222008698/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-008698
- JSON: https://secwatch.observer/filing/0001493152-22-008698.json
- Plain text: https://secwatch.observer/filing/0001493152-22-008698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.